| FINK, A. M., S. BOTTCHER, M. RITGEN, K. FISCHER, N. PFLUG, B. EICHHORST, C. M. WENDTNER, A. BUHLER, T. ZENZ, P. STAIB, Jiří MAYER, M. HENSEL, G. HOPFINGER, Marie WENGER, G. FINGERLE-ROWSON, H. DOHNER, M. KNEBA, S. STILGENBAUER, R. BUSCH, M. HALLEK and D. WINKLER. Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab. Leukemia. LONDON: NATURE PUBLISHING GROUP, 2013, vol. 27, No 9, p. 1949-1952. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/leu.2013.190. |
Other formats:
BibTeX
LaTeX
RIS
@article{1136283,
author = {Fink, A. M. and Bottcher, S. and Ritgen, M. and Fischer, K. and Pflug, N. and Eichhorst, B. and Wendtner, C. M. and Buhler, A. and Zenz, T. and Staib, P. and Mayer, Jiří and Hensel, M. and Hopfinger, G. and Wenger, Marie and FingerleandRowson, G. and Dohner, H. and Kneba, M. and Stilgenbauer, S. and Busch, R. and Hallek, M. and Winkler, D.},
article_location = {LONDON},
article_number = {9},
doi = {http://dx.doi.org/10.1038/leu.2013.190},
keywords = {CHRONIC LYMPHOCYTIC-LEUKEMIA; TRIAL; SURVIVAL; QUANTIFICATION; PROGRESSION},
language = {eng},
issn = {0887-6924},
journal = {Leukemia},
title = {Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab},
volume = {27},
year = {2013}
}
TY - JOUR
ID - 1136283
AU - Fink, A. M. - Bottcher, S. - Ritgen, M. - Fischer, K. - Pflug, N. - Eichhorst, B. - Wendtner, C. M. - Buhler, A. - Zenz, T. - Staib, P. - Mayer, Jiří - Hensel, M. - Hopfinger, G. - Wenger, Marie - Fingerle-Rowson, G. - Dohner, H. - Kneba, M. - Stilgenbauer, S. - Busch, R. - Hallek, M. - Winkler, D.
PY - 2013
TI - Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab
JF - Leukemia
VL - 27
IS - 9
SP - 1949-1952
EP - 1949-1952
PB - NATURE PUBLISHING GROUP
SN - 08876924
KW - CHRONIC LYMPHOCYTIC-LEUKEMIA
KW - TRIAL
KW - SURVIVAL
KW - QUANTIFICATION
KW - PROGRESSION
N2 - Chemoimmunotherapies like the combination of fludarabine, cyclophosphamide, and rituximab (FCR) achieve response rates as high as 95% in patients with previously untreated chronic lymphocytic leukemia (CLL).1 Further improvements in clinical outcome will therefore mainly depend on attaining more durable remissions in those responders who suffer an early relapse. In general, progression of disease within 24 months after intensive chemoimmunotherapy is regarded as unsatisfactory2 and might be associated with a shortened overall survival.
ER -
FINK, A. M., S. BOTTCHER, M. RITGEN, K. FISCHER, N. PFLUG, B. EICHHORST, C. M. WENDTNER, A. BUHLER, T. ZENZ, P. STAIB, Jiří MAYER, M. HENSEL, G. HOPFINGER, Marie WENGER, G. FINGERLE-ROWSON, H. DOHNER, M. KNEBA, S. STILGENBAUER, R. BUSCH, M. HALLEK and D. WINKLER. Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab. \textit{Leukemia}. LONDON: NATURE PUBLISHING GROUP, 2013, vol.~27, No~9, p.~1949-1952. ISSN~0887-6924. Available from: https://dx.doi.org/10.1038/leu.2013.190.
|
